Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis

被引:143
作者
Lee, Sang Hun [1 ,2 ]
Jeong, Dongjun [3 ]
Han, Yong-Seok [1 ]
Baek, Moo Jun [4 ]
机构
[1] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea
[2] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan 330930, South Korea
[3] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan 330930, South Korea
[4] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan 330930, South Korea
基金
新加坡国家研究基金会;
关键词
Angiogenesis inhibitors; Vascular endothelial growth factor receptors; Cell hypoxia; Tumor microenvironment; HYPOXIA-INDUCIBLE FACTORS; FACTOR GENE-EXPRESSION; ANTI-VEGF TREATMENT; FACTOR-C; INHIBITS ANGIOGENESIS; MONOCLONAL-ANTIBODY; CANCER; CELLS; METASTASIS; CYCLOOXYGENASE-2;
D O I
10.4174/astr.2015.89.1.1
中图分类号
R61 [外科手术学];
学科分类号
摘要
The shaping of new blood vessels is a significant event in cancer growth and metastasis. Therefore, the molecular system of cancer angiogenesis has garnered considerable interest in cancer research. The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process. Activation of the VEGF/VEGF-receptor pathway initiates signaling cascades that promote endothelial cell growth, migration, and differentiation. Recently, VEGF was shown to play a role in the recruitment of bone marrow-derived endothelial progenitor cells to neovascularization sites. The role of VEGF in promoting tumor angiogenesis and the occurrence of human cancers has led to the rational design and development of agents that selectively target this pathway. Moreover, these anti-VEGFNEGF receptor agents show therapeutic potential by inhibition of angiogenesis and tumor growth in preclinical models. In this review, we summarize the role of the VEGF pathway during tumor angiogenesis.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 81 条
[1]   Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells [J].
Akagi, M ;
Kawaguchi, M ;
Liu, W ;
McCarty, MF ;
Takeda, A ;
Fan, F ;
Stoeltzing, O ;
Parikh, AA ;
Jung, YD ;
Bucana, CD ;
Mansfield, PF ;
Hicklin, DJ ;
Ellis, LM .
BRITISH JOURNAL OF CANCER, 2003, 88 (05) :796-802
[2]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[3]   All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells [J].
Bairey, O ;
Boycov, O ;
Kaganovsky, E ;
Zimra, Y ;
Shaklai, M ;
Rabizadeh, E .
LEUKEMIA RESEARCH, 2004, 28 (03) :243-248
[4]   Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies [J].
Bellamy, WT .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :551-559
[5]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[6]  
Bouvet M, 1998, CANCER RES, V58, P2288
[7]   Arachidonic acid as a bioactive molecule [J].
Brash, AR .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (11) :1339-1345
[8]   Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice [J].
Bruns, CJ ;
Shrader, M ;
Harbison, MT ;
Portera, C ;
Solorzano, CC ;
Jauch, KW ;
Hicklin, DJ ;
Radinsky, R ;
Ellis, LM .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (02) :101-108
[9]   Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment [J].
Budhu, Anuradha ;
Forgues, Marshonna ;
Ye, Qing-Hai ;
Jia, Hu-Liong ;
He, Ping ;
Zanetti, Krista A. ;
Kammula, Udai S. ;
Chen, Yidong ;
Qin, Lun-Xiu ;
Tang, Zhao-You ;
Wang, Xin Wei .
CANCER CELL, 2006, 10 (02) :99-111
[10]  
Casanova ML, 2002, CANCER RES, V62, P3402